Movement Alert｜Eli Lilly Intraday Rise 3.48% in Regular Trading, Oncology Clinical Trial Collaboration Advances

Market Focus10-15 22:05

On October 15, Eli Lilly rose 3.48% in Regular Trading, trading at $1261.5 per share, with turnover of $796 million.

The move coincided with a newly disclosed oncology clinical trial collaboration and supply agreement involving Adlai Nortye, Eli Lilly, and Merck KGaA.

Under the agreement, Eli Lilly will provide cetuximab at no cost for US trial sites, while Merck KGaA will supply the drug for sites in Australia and China. The global phase 1 study will evaluate Adlai Nortye's investigational cancer drug AN4035 as monotherapy and in combination with cetuximab in patients with tumor-driving CEACAM5 and RAS biomarkers, with endpoints including safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. Separately, investor sentiment has also been supported by expectations ahead of Eli Lilly's October 29 earnings report for strong volume growth and a possible guidance increase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment